Polypharmacy Predicts Onset and Transition of Frailty, Malnutrition, and Adverse Outcomes in Peritoneal Dialysis Patient.

[1]  B. C. Kwan,et al.  Predictors and prognostic significance of persistent fluid overload: A longitudinal study in Chinese peritoneal dialysis patients , 2021, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[2]  K. Chow,et al.  Impact of frailty and its inter-relationship with lean tissue wasting and malnutrition on kidney transplant waitlist candidacy and delisting. , 2021, Clinical nutrition.

[3]  K. Jager,et al.  Polypharmacy and medication use in patients with chronic kidney disease with and without kidney replacement therapy compared to matched controls , 2021, Clinical Kidney Journal.

[4]  K. Chow,et al.  Progression in Physical Frailty in Peritoneal Dialysis Patients , 2021, Kidney and Blood Pressure Research.

[5]  M. Giroux,et al.  Pharmacokinetics of Tobramycin Administered at the Beginning of Intermittent Hemodialysis Session (ESRD Study) , 2021, Canadian journal of kidney health and disease.

[6]  B. Zhao,et al.  Frailty as a Predictor of Negative Health Outcomes in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. , 2020, Journal of the American Medical Directors Association.

[7]  Connie M. Rhee,et al.  Polypharmacy, hospitalization, and mortality risk: a nationwide cohort study , 2020, Scientific Reports.

[8]  K. Chow,et al.  Interaction between central obesity and frailty on the clinical outcome of peritoneal dialysis patients , 2020, PloS one.

[9]  M. Debowska,et al.  Phosphate clearance in peritoneal dialysis , 2020, Scientific Reports.

[10]  J. Carrero,et al.  KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. , 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  K. Pawlaczyk,et al.  Nutritional Status in Peritoneal Dialysis: Nutritional Guidelines, Adequacy and the Management of Malnutrition , 2020, Nutrients.

[12]  H. Rupprecht,et al.  Adverse Drug Events in Patients with Chronic Kidney Disease Associated with Multiple Drug Interactions and Polypharmacy , 2020, Drugs & Aging.

[13]  C. Miki,et al.  Effects of Protein-Energy Wasting (PEW) and hyperphosphatemia on the prognosis in Japanese maintenance hemodialysis patients: A five-year follow-up observational study. , 2020, Clinical nutrition ESPEN.

[14]  B. C. Kwan,et al.  Depression does not predict clinical outcome of Chinese peritoneal Dialysis patients after adjusting for the degree of frailty , 2020, BMC Nephrology.

[15]  A. Kurilshikov,et al.  Impact of commonly used drugs on the composition and metabolic function of the gut microbiota , 2020, Nature Communications.

[16]  Jenq-Wen Huang,et al.  Contributors, risk associates, and complications of frailty in patients with chronic kidney disease: a scoping review , 2019, Therapeutic advances in chronic disease.

[17]  A. Köttgen,et al.  Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study , 2019, Clinical kidney journal.

[18]  A. Gafter-Gvili,et al.  Iron Deficiency Anemia in Chronic Kidney Disease , 2019, Acta Haematologica.

[19]  G. Nadkarni,et al.  National Trends in Emergency Room Visits of Dialysis Patients for Adverse Drug Reactions , 2018, American Journal of Nephrology.

[20]  B. C. Kwan,et al.  Depression and Physical Frailty Have Additive Effect on the Nutritional Status and Clinical Outcome of Chinese Peritoneal Dialysis , 2018, Kidney and Blood Pressure Research.

[21]  A. Garg,et al.  A Province-wide, Cross-sectional Study of Demographics and Medication Use of Patients in Hemodialysis Units Across Ontario , 2018, Canadian journal of kidney health and disease.

[22]  Gillian E. Caughey,et al.  What is polypharmacy? A systematic review of definitions , 2017, BMC Geriatrics.

[23]  M. R. Silveira,et al.  Association between medication regimen complexity and pharmacotherapy adherence: a systematic review , 2017, European Journal of Clinical Pharmacology.

[24]  Q. Qian,et al.  Protein Nutrition and Malnutrition in CKD and ESRD , 2017, Nutrients.

[25]  J. Coresh,et al.  Frailty, Kidney Function, and Polypharmacy: The Atherosclerosis Risk in Communities (ARIC) Study. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  A. Dębska-Ślizień,et al.  Impact of gender and dialysis adequacy on anaemia in peritoneal dialysis , 2017, International Urology and Nephrology.

[27]  Chih-Ching Lin,et al.  Fixed dose of long‐acting erythropoietic stimulating agents at higher frequency improves appetite, reduces inflammation and corrects anaemia in patients on haemodialysis , 2016, Clinical and experimental pharmacology & physiology.

[28]  Gregory M. Peterson,et al.  Nonadherence to Medication Therapy in Haemodialysis Patients: A Systematic Review , 2015, PloS one.

[29]  Andrew T Chan,et al.  Trends in Prescription Drug Use Among Adults in the United States From 1999-2012. , 2015, JAMA.

[30]  Wai Lun Cheung,et al.  Renal registry in Hong Kong—the first 20 years , 2015, Kidney international supplements.

[31]  J. Adachi,et al.  The relationship between long-term proton pump inhibitor therapy and skeletal frailty , 2015, Endocrine.

[32]  S. Mitra,et al.  Medication burden in CKD-5D: impact of dialysis modality and setting , 2014, Clinical kidney journal.

[33]  K. Griva,et al.  Non-Adherence in Patients on Peritoneal Dialysis: A Systematic Review , 2014, PloS one.

[34]  Jin-Bor Chen,et al.  Relationship between Kt/V urea-based dialysis adequacy and nutritional status and their effect on the components of the quality of life in incident peritoneal dialysis patients , 2012, BMC Nephrology.

[35]  John K Marshall,et al.  Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression , 2007, The American Journal of Gastroenterology.

[36]  J. Bargman,et al.  Guideline on Targets for Solute and Fluid Removal in Adult Patients on Chronic Peritoneal Dialysis , 2006, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[37]  R. Valuck,et al.  A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. , 2004, Journal of clinical epidemiology.

[38]  E. Björnsson,et al.  Overuse of acid suppressant drugs in patients with chronic renal failure. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[39]  Tze-Wah Kao,et al.  Relationship between Dialysis Adequacy and Quality of Life in Long-Term Peritoneal Dialysis Patients , 2000, Peritoneal Dialysis International.